✦ LIBER ✦

CROSS-RESISTANCE AND COMBINED CYTOTOXIC EFFECTS OF PACLITAXEL AND CISPLATIN IN BLADDER CANCER CELLS

✍ Scribed by PU, YEONG-SHIAU; CHEN, JUN; HUANG, CHAO-YUAN; GUAN, JING-YI; LU, SHIU-HUI; HOUR, TZYH-CHYUAN

Book ID: 122666636
Publisher: Lippincott Williams and Wilkins
Year: 2001
Tongue: English
Weight: 71 KB
Volume: 165
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)66298-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MP39-05 SYNERGISTIC ANTITUMOR EFFECT OF

MP39-05 SYNERGISTIC ANTITUMOR EFFECT OF SAHA AND CISPLATIN IN CISPLATIN RESISTANT BLADDER CANCER CELL LINE

✍ Kook, Ha Rim; Lee, Young Ju; Yeon, Jae Seung; Lee, Han Sol; Noh, Choong Hee; Kim 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 353 KB

Mechanism of cross-resistance to cisplat

Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line

✍ Shivendra V. Singh; Bing H. Xu; Jitesh P. Jani; Erling O. Emerson; Mary G. Backe 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 730 KB

This study was undertaken to elucidate the mechanism@) of cross-resistance to cisplatin (CDDP) in a mitomycin C (MMC)resistant human bladder cancer cell line, J82/MMC. The J82/ MMC cell line displayed 2-to 3-fold cross-resistance to CDDP and carboplatin when compared to the parental )82/WT cells. Dr

Pharmacology of the paclitaxel–cisplatin

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

Biochemical mechanism of cross-resistanc

Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line

✍ Richard J Bleicher; Hong Xia; Howard A Zaren; Shivendra V Singh 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 161 KB

Evaluation of paclitaxel (taxol), cispla

Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay

✍ M. Untch; B.-U. Sevin; J.P. Perras; R. Angioli; A. Untch; R.D. Hightower; O. Koe 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Evaluation of Paclitaxel (Taxol), Cispla

Evaluation of Paclitaxel (Taxol), Cisplatin, and the Combination Paclitaxel-Cisplatin in Ovarian Cancer in Vitro with the ATP Cell Viability Assay

✍ Michael Untch; Bernd-Uwe Sevin; James P. Perras; Roberto Angioli; Andrea Untch; 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 323 KB